Decitabine

Nucleoside Metabolic Inhibitor — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Decitabine is an ofp drug in the Nucleoside Metabolic Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2006. Its mechanism of action is classified as Nucleic Acid Synthesis Inhibitors. DrugCentral lists 2 molecular targets, including DNMT1 and DNMT3A. Recorded indications include Acute myeloid leukemia, disease and Myelodysplastic syndrome.

• Approval status: ofp (first approved 2006 by the FDA).
• Drug class: Nucleoside Metabolic Inhibitor.
• Mechanism of action: Nucleic Acid Synthesis Inhibitors.
• Molecular targets: DNMT1 and DNMT3A (2 listed in DrugCentral).
• Indications: Acute myeloid leukemia, disease and Myelodysplastic syndrome.
• ATC code: L01BC08 (Pyrimidine analogues).
• Molecular formula: C8H12N4O4; molecular weight 228.21 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Acute myeloid leukemia, disease
• Myelodysplastic syndrome

Contraindications (7)

• Breastfeeding (mother)
• Diabetes mellitus
• Disease of liver
• Kidney disease
• Neutropenic disorder
• Pregnancy, function
• Thrombocytopenic disorder

Mechanism & targets

• Mechanism of action (MoA): Nucleic Acid Synthesis Inhibitors
• Established pharmacologic class: Nucleoside Metabolic Inhibitor

Molecular targets (2)

Target	Gene	Action	Activity
DNA (cytosine-5)-methyltransferase 1	DNMT1	inhibitor	IC50 7.52
DNA (cytosine-5)-methyltransferase 3A	DNMT3A	inhibitor	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2006-05-02	FDA	—	Astex Pharmaceuticals, Inc.	Yes

ATC classification

ATC code	Therapeutic hierarchy
L01BC08	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › ANTIMETABOLITES › Pyrimidine analogues
L01BC58	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › ANTIMETABOLITES › Pyrimidine analogues

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Myelosuppression	910.3
Febrile neutropenia	810.3
Acute myeloid leukaemia	331.7
Neutropenia	319.3
Bone marrow failure	252.4
Acute myeloid leukaemia recurrent	240.4
Thrombocytopenia	237.5
Pneumonia	222.9
Sepsis	222.8
Pancytopenia	201.8
Off label use	199.2
Disease progression	178.6

Chemical structure

• Molecular formula: C₈H₁₂N₄O₄
• Molecular weight: 228.21 g/mol
• CAS number: —
• InChIKey: XAUDJQYHKZQPEU-KVQBGUIXSA-N
• PubChem CID: 451668

NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Decitabine used for?

DrugCentral lists the following indications for Decitabine: Acute myeloid leukemia, disease and Myelodysplastic syndrome.

How does Decitabine work?

Decitabine is classified as Nucleic Acid Synthesis Inhibitors; its molecular targets in DrugCentral include DNMT1 (inhibitor) and DNMT3A (inhibitor).

When was Decitabine first approved?

Decitabine was first approved by the FDA in 2006.

What drug class does Decitabine belong to?

Decitabine is in the Nucleoside Metabolic Inhibitor class.

What is the chemical formula of Decitabine?

Decitabine has the molecular formula C8H12N4O4 and a molecular weight of 228.21 g/mol.

Sources

• DrugCentral drug card 790 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1201129 — compound record and bioactivity
• PubChem CID 451668 — chemical identifiers
• DrugBank DB01262 — drug record
• FDA UNII 776B62CQ27 — substance identity
• DailyMed: FDA labels for Decitabine — current prescribing information (label search)
• UniProt P26358 (DNMT1) — target protein
• UniProt Q9Y6K1 (DNMT3A) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.